Furthermore, wt TP53 LOF is seen in patients with Li-Fraumeni syndrome; affected individuals develop AML at a frequency comparable to that of healthy individuals with other TP53 mutations, but they manifest more aggressive disease (Prokocimer et al., 2017; Boettcher et al., 2019; Daver et al., 2022; Shah et al., 2023). This evidence concerns the gene TP53 and Li-Fraumeni syndrome.